ImmuPharma plc
OTC: IMMPF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Paul McCarthy XIV, FCCA, MBA
- Employees
- 14
- Headquarters
- London, United Kingdom
- IPO year
- 2017
- Market cap
- $28.3M
- Website
- https://www.immupharma.co.uk
Loading IMMPF…
Loading profile data…Frequently asked questions about IMMPF
What does ImmuPharma plc (IMMPF) do?
ImmuPharma plc, established in London, United Kingdom, in 1999, is a biopharmaceutical company dedicated to discovering and advancing peptide-based therapeutics. These treatments are focused on tackling conditions related to autoimmunity, inflammation, and various infections. The company's primary drug candidate, Lupuzor, an autophagy immunomodu...
Where does IMMPF trade?
ImmuPharma plc (IMMPF) trades on the Other OTC.
What sector is IMMPF in?
ImmuPharma plc (IMMPF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ImmuPharma plc?
Timothy Paul McCarthy XIV, FCCA, MBA is the chief executive officer of ImmuPharma plc (IMMPF).
Where is ImmuPharma plc headquartered?
ImmuPharma plc is headquartered in United Kingdom.
Does IMMPF pay a dividend?
Yes — ImmuPharma plc (IMMPF) paid a trailing twelve-month dividend of USD 3.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did IMMPF go public?
ImmuPharma plc (IMMPF) completed its initial public offering in 2017.